Bmhs.Jk
BMHS.JK operates in the healthcare sector, providing healthcare facilities and services, and is classified under biotechnology activities.
Business. BMHS.JK operates in the healthcare sector, providing healthcare facilities and services, and is classified under biotechnology activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BMHS.JK operates in the healthcare sector, providing healthcare facilities and services, and is classified under biotechnology activities.
BMHS.JK has a market price of 185.00 IDR, with a market capitalization of 1,591,631,992,560.00 IDR. The company's price-to-earnings ratio is 128.16, and its price-to-book ratio is 0.82, indicating a relatively low valuation compared to its book value. The company's liquidity is assessed as medium, with a current ratio of 1.62, suggesting it has sufficient short-term assets to cover its short-term liabilities.
In terms of profitability, BMHS.JK has a return on equity of 0.64% and a return on assets of 0.31%, which are below the industry average for healthcare facilities and services. The company's operating income is 89,879,196,850.00 IDR, and its net income is 12,418,961,320.00 IDR, indicating a relatively modest profit margin. The company's debt-to-equity ratio is 0.7, suggesting a moderate level of leverage.
BMHS.JK's revenue is concentrated in a single segment, with no disclosed geographic diversification. The company's total revenue is 1,614,340,771,510.00 IDR, and it has a gross profit of 744,492,466,110.00 IDR. The company's operating cash flow is 250,621,859,690.00 IDR, but its free cash flow is negative at -81,026,763,920.00 IDR, indicating that the company is not generating enough cash to cover its capital expenditures.
The company's growth trajectory is mixed. Its capital expenditure is -218,905,414,890.00 IDR, indicating a significant investment in long-term assets. However, the company's free cash flow is negative, suggesting that it may need to seek additional financing to fund its operations. Analysts have set a mean price target of 220.00 IDR, indicating a potential upside from the current market price.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. However, the company has a key flag indicating that its net cash is negative after subtracting total debt, which could pose a challenge to its financial stability. The company's long-term debt is 1,355,787,365,220.00 IDR, which is a significant portion of its total liabilities.
Recent events and filings have not been disclosed in the provided data, so no specific recent developments can be cited. However, the company's financial performance and risk profile suggest that it may need to manage its debt and improve its profitability to sustain long-term growth.
- BMHS.JK has a relatively low price-to-book ratio, indicating a potential undervaluation.
- The company's return on equity and return on assets are below the industry average, suggesting a need for improved profitability.
- BMHS.JK's free cash flow is negative, indicating a potential need for additional financing.
- The company's liquidity is assessed as medium, with a current ratio of 1.62.
- Analysts have set a mean price target of 220.00 IDR, indicating a potential upside from the current market price.
- **margin_outlook_rationale**: The company's gross profit margin is 46.1%, which is in line with the industry average, but its operating margin is 5.6%, which is below the industry average, indicating a need for cost management.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- BMHS.JK Market data — financials · 2026-05-27
- Bundamedik Tbk PT Market data — analyst estimates · 2026-05-27